Inebilizumab (AChR-positive gMG or MuSKR-positive gMG)

·        Company: Amgen

·        Trial: MINT (Phase 3, estimated completion 29/11/27, no UK trial sites)

Mezagitamab (AChR-positive gMG or MuSKR-positive gMG)

·        Company: Takeda

·        Trial: Phase 2, completed 12/7/22

Satralizumab (AChR-positive gMG or MuSKR-positive gMG or LRP4R-positive gMG)

·        Company: Roche

·        Trial: LUMINESCE (Phase 3, estimated completion 2/9/24, no UK trial sites)

Telitacicept (AChR-positive gMG or MuSKR-positive gMG)

·        Company: RemeGen Co

·        Trial: RemeMG (Phase 3, estimated completion 7/2027, not yet recruiting)